Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of brilliant blue G to preparation of drugs for human immunodeficiency virus glycoprotein 120 induced neuropathic pain

A technology for human immunodeficiency and neuropathic pain, applied in nervous system diseases, drug combinations, antipyretics, etc., can solve problems such as unclear effects

Inactive Publication Date: 2017-04-19
NANCHANG UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is not clear what P2X in DRG 7 The role of receptors in NPP complicated by HIV infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of brilliant blue G to preparation of drugs for human immunodeficiency virus glycoprotein 120 induced neuropathic pain
  • Application of brilliant blue G to preparation of drugs for human immunodeficiency virus glycoprotein 120 induced neuropathic pain
  • Application of brilliant blue G to preparation of drugs for human immunodeficiency virus glycoprotein 120 induced neuropathic pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Oral or injectable Brilliant Blue G preparations suitable for the treatment of HIV gp120-induced neuropathic pain are prepared by methods known in the art.

Embodiment 2

[0022] Oral or injectable Brilliant Blue G preparations suitable for the treatment of diseases related to HIV gp120 complicated by nerve damage are prepared by methods known in the art.

Embodiment 3

[0024] Oral or injectable Brilliant Blue G preparations suitable for the treatment of HIV gp120 complicated with sensory neuroinflammation-related diseases are prepared by methods known in the art.

[0025] In a word, Brilliant Blue G can be used for oral administration, injection, buccal tablet or other local or systemic dosage forms for the prevention and treatment of the above-mentioned diseases.

[0026] In order to better understand the essence of the present invention, the following uses bright blue G for P2X 7 Experiments and results of receptor-mediated treatment of related diseases to prove the use of Brilliant Blue G.

[0027] 1. Materials and methods.

[0028] 1. Animals and grouping.

[0029] Healthy Sprague-Dawley (SD) rats were provided by the Department of Experimental Animal Science, School of Medicine, Nanchang University. Thirty healthy SD male rats, weighing about 200g, were randomly divided into 3 groups after 1 week of adaptive feeding, 10 rats in each ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of brilliant blue G to the preparation of drugs for human immunodeficiency virus glycoprotein 120 induced neuropathic pain. An experiment proves that the brilliant blue G can reduce expression of a P2X7 receptor of a dorsal root ganglion neuron, reduce the content of inflammatory cytokines-TNF-alpha receptor and IL-1beta and the ERK1 / 2 phosphorylation level of dorsal root ganglia of a human immunodeficiency virus glycoprotein 120, increase the IL-10 content of the rat dorsal root ganglia of the human immunodeficiency virus glycoprotein 120, inhibit noxious information transmission of the dorsal root ganglia, relieve nerve injury and injury stimulation of inflammatory substances, and reduce pain behaviors of rats with the human immunodeficiency virus glycoprotein 120 induced neuropathic pain, and can be applied to the preparation of drugs for diseases related to human immunodeficiency virus glycoprotein 1200 induced neuropathic pain and human immunodeficiency virus glycoprotein 120 induced nerve injury.

Description

technical field [0001] The present invention relates to the field of the invention of the application of human immunodeficiency virus glycoprotein 120gp120-induced neuropathic pain drugs, in particular to the application of Brilliant Blue G in the preparation of drugs for reducing neuropathic pain induced by human immunodeficiency virus glycoprotein 120gp120, and its effect Mechanism involves inhibition of purine 2X (P2X) in dorsal root ganglia 7 Receptor-mediated transmission of pain information. Background technique [0002] Human immunodeficiency virus (human immunodeficiency virus, HIV) infection can often lead to neurological cognitive, sensory and action dysfunction, leading to various neurological diseases, which can be life-threatening in severe cases. Patients with HIV infection complicated by peripheral neuropathy have sensory dysfunction in the distal limbs, which are distributed in a sock-like distribution. The feet are first painful. With the further developmen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/185A61P25/02A61P29/00
CPCA61K31/185
Inventor 梁尚栋吴炳彭力超邹丽芳刘双梅易智华赵珊红贾天宇李桂林张春平
Owner NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products